A5026683952- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Rheumatoid Arthritis Research and Therapies
- Child and Adolescent Health
- Systemic Lupus Erythematosus Research
- Pulmonary Hypertension Research and Treatments
- interferon and immune responses
- Ocular Diseases and Behçet’s Syndrome
- Intramuscular injections and effects
- IL-33, ST2, and ILC Pathways
- SARS-CoV-2 and COVID-19 Research
- Human Health and Disease
- Childhood Cancer Survivors' Quality of Life
- Renal Diseases and Glomerulopathies
- Cardiovascular Disease and Adiposity
- Kawasaki Disease and Coronary Complications
- Erythrocyte Function and Pathophysiology
- Pharmaceutical studies and practices
Scientific Center of Children's Health
2021-2025
Sechenov University
2020-2023
VA Nasonova Scientific Research Institute of Rheumatology
2021
The University of Western Australia
2021
Sir Charles Gairdner Hospital
2021
Center for Children
2020
Background: Immunosuppressive therapy (methotrexate and biological agents) for juvenile idiopathic arthritis (JIA) is associated with an increased risk of severe infections, higher infection rates, treatment interruptions, failure to achieve disease remission, recurrent flares. Our study aimed evaluate the safety efficacy simultaneous immunization 13-valent polysaccharide conjugate vaccines (PCV13) against S. pneumoniae (SP) Hemophilus influanzae type b infections (HibV) in children JIA...
Background A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack efficacy or safety concerns. Studies therapy switch regimens in sJIA are required. Methods Patients with who switched from tocilizumab (due safety) canakinumab (4 mg/kg every 4 weeks) and were hospitalized at the rheumatology department August 2012 July 2020 included. Primary outcomes 30% greater improvement based on...
Introduction The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D cryopyrin-associated but this treatment has not been assessed patients with undifferentiated AIDs (uAIDs). Our study aimed to assess the safety efficacy canakinumab uAIDs. Methods Information on 32 uAIDs was...
Systemic juvenile idiopathic arthritis (sJIA) is of one or more joints accompanied preceded by confirmed intermittent fever at least 3 days duration for 2 weeks in combination with the following features: transient (volatile) erythematous rash, generalized lymphadenopathy, hepatomegaly and/or splenomegaly, serositis. Prior to invention genetically engineered biological drugs (GEBDs), therapeutic options patients JIA were limited use nonsteroidal anti-inflammatory (NSAIDs),...
The efficacy of JAK-kinase inhibitors in autoimmune diseases is due to the peculiarities their pathogenesis, involvement various cytokines that trigger cascade inflammatory reactions, enhance transcriptional response disease-induced or disease-associated genes and potentiate production proinflammatory cytokines. Only tofacitinib currently approved for use pediatric rheumatic diseases. Given literature data on other adult diseases, we assume possibility patients. Objective. To evaluate safety...
New coronavirus infection (COVID-19) is an acute respiratory disease caused by the SARS-CoV-2 coronavirus. Tixagevimab+cilgavimab has been developed for prevention and treatment of COVID-19. The purpose this research was to evaluate safety use two-component drug monoclonal antibodies (tixagevimab+cilgavimab) pre-exposure prophylaxis new in children with rheumatic diseases (RDs). Materials methods used: a single-center retrospective study prospective stage had carried out that included 300...
Severe acute respiratory syndrome virus SARS-CoV-2 is associated with the phenomenon of immune system dysregulation, which may serve as a trigger for development autoimmune diseases and secondary hemophagocytic (vHPS). Objective. To determine peculiarities clinical laboratory manifestations sHPS in children rheumatic (RD) developed after NCI (COVID-19). Patients methods. The study included 116 pediatric patients RH who underwent examination treatment at rheumatology department National...
Autoinflammatory diseases (AIDs) are a group of orphan, genetically determined conditions caused by dysregulation the innate immune system, leading to hyperproduction inflammatory mediators and activation autoinflammation. The role in pathogenesis most AIDs belongs excessive secretion proinflammatory cytokines, mainly interleukin-1 (IL-1), which makes it possible successfully use engineered biological drugs (GEBDs) from IL-1 inhibitors for treatment patients with AIDs. high efficacy...
Objective. To evaluate the pharmacokinetics (PK), efficacy, and safety of direct interleukin-6 inhibitor olokizumab (OKZ) when used in adolescent patients with active juvenile idiopathic polyarthritis (JIA), ineffectiveness or intolerance to methotrexate. Patients methods. The results OKZ therapy at a dose 64 mg every 4 weeks during 24 open-label study were analysed. parameters PK, dynamics serum concentration C-reactive protein (CRP), adverse events (AEs) evaluated. Results. Sixteen...
Undifferentiated autoinflammatory diseases (uAIDs) constitute a group of rare that do not correspond in their phenotype and genotype to known monogenic AIDs. They often manifest as juvenile arthritis, particularly its systemic variant. A comprehensive understanding the clinical, laboratory, genetic characteristics undifferentiated AIDs is essential for timely diagnosis initiation targeted therapy. This approach can reduce risk complications, disability, improve prognosis. Objective. To...
Background Uveitis is the most common extra-articular manifestation of JIA which may lead to sight-threatening ocular complications. Topical corticosteroids are still used in initial treatment for JIA-associated uveitis. The goal these patients should be topical corticosteroid-free remission and prevention recurrences. commonly corticosteroid-sparing immunomodulatory TNF-α inhibitors (TNFi), especially adalimumab. Currently, limited data available about when or how stop adalimumab uveitis...
Background . Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates the genetically engineered biologic drugs (GEBD) effects on vaccination results also remain controversial. Objective The aim study was to explore PCV-13 efficacy patients SJIA and who treatment monoclonal antibodies against interleukin 6 receptor (tocilizumab) 8 beta (canakinumab). Methods included under age 18 remission or...
Background: The efficacy of tocilizumab for treatment patients with systemic juvenile idiopathic arthritis (sJIA) was demonstrated before. We want to describe drug survival based on data from a single-center observation. Objectives: To analyze the in sJIA treated at National Medical Research Center Children`s health, Moscow, Russia. Methods: records (TOC) were analyzed retrospectively Results: One hundred ninety-two presenting included this observation, median age initiation 7,2...
Interleukin-1β is one of the key cytokines mediating development clinical manifestations systemic juvenile idiopathic arthritis (sJIA) in early (febrile) and late phases disease. The implementation interleukin-1β blockers into routine practice has significantly changed course this severe Objective. To assess efficacy safety canakinumab patients with sJIA. Patients methods. This study included 73 sJIA who received canakinumab. Treatment was initiated Department Rheumatology, National Medical...
Background. A register is a critical component of the healthcare system. It consists informational part (number patients, spectrum and severity pathology, dynamics each patient's condition, administration specific drugs, therapeutic effects) an analytical (treatment efficacy, planning individual regional needs for drugs effects, development evaluation management protocols, etc.). In Russia, despite existence National Federal Register, number parameters collected limited; Register lacks...
Juvenile idiopathic arthritis (JIA) is of unknown cause lasting more than 6 weeks, which starts in children under 16 years old with the exclusion other joint disorder. According to recommendations for treatment JIA, patients who does not responded antirheumatic therapy, we prescribe biological primarily TNF-alpha inhibitors. Despite their high effectiveness, some patients, inhibitors has no proper therapeutic effect, requires studying possibility using particular- rituximab. Objective. To...
Juvenile arthritis (Syn.: Systemic adolescent idiopathic arthritis; hereinafter referred to as the JA, sJA) is most complex pathogenesis, severe process, and poorly predicted variant of arthritis. The characteristic sJA process development life-threatening complications, which may lead further functional multi organ failure, delayed physical development, patient disability. In this regard, it necessary diagnose disease correctly in early stages. Therefore, children suspected having should be...
Systemic juvenile idiopathic arthritis (syn.: with systemic onset; hereinafter referred to as sJIA) is one of the most severe variants arthritis, in which at beginning disease it often not joint damage that comes fore, but manifestations such fever, rash, hepatosplenomegaly, lymphadenopathy and serositis. Tumor necrosis factor-α (TNF-α) inhibitors, successfully used therapy JIA without manifestations, are effective patients JIA. Thus, according BIKER registry (Germany), remission was...
Background: Canakinumab (CAN) is often used as second biologics in juvenile idiopathic arthritis with active systemic features (sJIA). However, there are little information about its long-term efficacy and safety. Objectives: To evaluate the effectiveness safety of CAN a after tocilizumab (TOC) sJIA patients depending on duration disease. Methods: Thirty-one were enrolled this study: group early (with shorter than 2 years, 19 patients) late longer 12 patients). At baseline, was collected...
Background: Early-onset form of systemic juvenile idiopathic arthritis (sJIA) often presents severe disease course. Choosing the optimal therapy option as first-line treatment is necessary for rapid improvement patients’ quality live and prevention further radiologic progression. Objectives: To evaluate long-term effectiveness safety tociliizumab (TOC) in sJIA patients depending on duration treated National Medical Research Center Children`s health, Moscow, Russia. Methods: The study was...
Background: Cryopyrine-associated periodic syndromes (CAPS) are a group of rare congenital auto-inflammatory diseases (AID) that include such as familial cold syndrome (FCAS), Muckle-Wells (MWS), and CINCA/NOMID syndrome. At present, there limited data on demographic clinical features children with CAPS in Russia. Objectives: To reveal demographic, genotype phenotype characteristics patients at the National Medical Research Center Children`s health, Moscow, Methods: Retrospective study...
Background: Anti-IL-17A biologic drug secukinumab (SEC) proved to be effective for treatment of psoriatic arthritis. However data about its efficacy in juvenile idiopathic arthritis (JIA) are restricted off-label experience. Objectives: To evaluate the effectiveness and safety SEC JIA patients National Medical Research Center Children`s health, Moscow, Russia. Methods: 25 started therapy from 12/2017 11/2019 single-center prospective study. 3 withdrew treatment: two (8%) due AE (1 - allergy...
Background: The need for continuous use of immunosuppressive drugs leads to increased risk developing infectious diseases in children with juvenile idiopathic arthritis systemic manifestation (sJIA). Questions about choosing the optimal vaccination time and effect different classes therapy on effectiveness are still open. Objectives: To study clinical laboratory PCV13-vaccination sJIA tocilizumab (TOC) canakinumab (CAN) treatment depending disease activity stage. Methods: Prospective cohort...
Background: Results from various phase 3 clinical studies have demonstrated the efficacy of canakinumab to treat patients with systemic juvenile idiopathic arthirtis (sJIA). However, limited information is available on long-term and safety this drug children sJIA. Objectives: To evaluate in sJIA treated at National Medical Research Center Children`s health, Moscow, Russia. Methods: This was a prospective, single-center study that included (CAN)-naive diagnosed following International League...
Background Systemic juvenile idiopathic arthritis (sJIA) is the rarest variant of arthritis, characterized by severe course, frequent exacerbations, development life-threatening extra-articular manifestations and complications, which requires use expensive medications hospitalizations patients. In Russian Federation, provision medicines to patients with sJIA carried out at expense federal budget, in this regard, Federal Register was created 2018. Objectives To analyze biologic therapy...